Prefilled Syringe of Faricimab-Svoa Approved by FDA for Leading Causes of Vision Loss
July 8th 2024Following the previous FDA approval of faricimab-svoa to treat some of the leading causes of vision loss, the Administration has approved a single-dose prefilled syringe of the drug which could lead to safer and more efficient administration while easing patient burden.
FDA Grants Orphan Drug Designation to RCT1100 For Primary Ciliary Dyskinesia
Published: July 1st 2024 | Updated: July 1st 2024RCT1100 is designed to deliver DNAI1 mRNA directly to affected airways through an inhaled nebulizer and fills an urgent unmet need in the treatment of those with primary ciliary dyskinesia.